Calgary, Alberta — November 19, 2025 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has received conditional approval from the TSX Venture Exchange (TSXV) for a non-brokered private placement of CDN $280,594.
The offering involves the issuance of 2,244,752 common shares at CDN $0.125 per share, according to the announcement made on November 18, 2025. The investor is at arm’s length from Hemostemix and is not a related party to the company.
Hemostemix, founded in 2003, is an autologous stem cell therapy company known for its VesCell™ (ACP-01) technology. This technology is offered to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia in Florida, as permitted under Florida’s SB 1768.
The company intends to use the proceeds from the private placement for general working capital, supporting its operational expenses, and business development activities. Hemostemix confirms there are no undisclosed material facts or changes about the company.
The TSXV’s final approval will enable Hemostemix to issue the 2,244,752 common shares. Securities issued in connection with the offering will be subject to a four-month hold period from the closing date, as per Canadian securities laws, in addition to other restrictions under applicable securities laws of jurisdictions outside Canada.
Hemostemix highlights its patented VesCell™ (ACP-01) therapy and a recent peer-reviewed article in Cells (June 29, 2025) which supports how ACP-01 and NCP-01 may improve brain-computer interface performance by reducing inflammation, promoting angiogenesis and synaptic plasticity, potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects, with results published in 11 peer-reviewed publications.
The company emphasizes the safety, clinical relevance, and statistical significance of ACP-01 as a treatment for various conditions, citing a Phase II clinical trial for chronic limb threatening ischemia with results published in the Journal of Biomedical Research & Environmental Science. The study reported a 0% mortality rate and wound healing in 83% of patients followed for up to 4.5 years, compared to a 50% five-year mortality rate in the CLTI patient population, as reported by UBC and U of T at the 41st meeting of vascular surgeons.
Thomas Smeenk, President, CEO & Co-Founder:
EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
